Stockreport

Pulmonx Announces Presentation of Clinical Data from the AeriSeal® CONVERT Trial and 5-Year Follow-up Data from the LIBERATE Study at the European Respiratory Society Congress 2024

Pulmonx Corporation  (LUNG) 
US:NASDAQ Investor Relations: investor.prolunginc.com/investor-relations
PDF CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year durability data from LIBERATE study demons [Read more]